aripiprazole has been researched along with 1-methyl-3-isobutylxanthine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burris, KD; Kikuchi, T; Molinoff, PB; Molski, TF; Ryan, E; Tottori, K; Xu, C; Yocca, FD | 1 |
1 other study(ies) available for aripiprazole and 1-methyl-3-isobutylxanthine
| Article | Year |
|---|---|
Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Antipsychotic Agents; Aripiprazole; CHO Cells; Colforsin; Cricetinae; Cyclic AMP; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; GTP-Binding Proteins; Humans; Piperazines; Quinolones; Radioligand Assay; Receptors, Dopamine D2; Signal Transduction; Spiperone | 2002 |